[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 174.129.66.66. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 137
Citations 0
Letters
March 14, 2012

Intracoronary Bone Marrow Mononuclear Cells After Myocardial Infarction

Author Affiliations

Author Affiliation: Interventional Cardiology Division, Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada (Qh.ly@montreal.ca).

JAMA. 2012;307(10):1022-1024. doi:10.1001/jama.2012.278

To the Editor: The LateTIME trial findings1 suggest a lack of benefit from intracoronary delivery of bone marrow mononuclear cells (BMCs) 2 to 3 weeks after primary percutaneous coronary intervention (PCI) in patients with myocardial infarction (MI) and depressed left ventricular (LV) function. However, further clarification is needed to better appreciate the study conclusions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×